Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Fabio Ciceri and Antonio Risitano.
Fabio Ciceri
Connection Strength
0.718
Antonio Risitano
  1. Author Correction: Complement as a target in COVID-19? Nat Rev Immunol. 2020 07; 20(7):448.
    View in: PubMed
    Score: 0.223
  2. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 06; 215:108450.
    View in: PubMed
    Score: 0.220
  3. Complement as a target in COVID-19? Nat Rev Immunol. 2020 06; 20(6):343-344.
    View in: PubMed
    Score: 0.220
  4. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin Immunol. 2020 11; 220:108598.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.